Background: According to the WHO classification of breast tumors, phyllodes tumors(PTs) are classified into the benign,
borderline, and malignant PTs. However, the subjectivity of WHO's
diagnostic criteria for PTs has brought some difficulties to pathological diagnosis work. In order to better understand the biological characteristics of PTs and the gene mutations related to
FDA approved treatments. Therefore we analyzed the potential
molecular features of PTs.
第一作者机构：[1]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714)：
Cai Lijing,Yue Meng,Zhao Jianing,et al.Multi Gene Testing Reveals Gene Mutations in Breast Lobular Tumors: Implications for Prognosis and Clinical Utility of Mutations[J].LABORATORY INVESTIGATION.2025,105(3):doi:10.1016/j.labinv.2024.102349.
APA：
Cai, Lijing,Yue, Meng,Zhao, Jianing&Liu, Yueping.(2025).Multi Gene Testing Reveals Gene Mutations in Breast Lobular Tumors: Implications for Prognosis and Clinical Utility of Mutations.LABORATORY INVESTIGATION,105,(3)
MLA：
Cai, Lijing,et al."Multi Gene Testing Reveals Gene Mutations in Breast Lobular Tumors: Implications for Prognosis and Clinical Utility of Mutations".LABORATORY INVESTIGATION 105..3(2025)
